OC.06.6 DO ANTICOAGULATION OR ANTIPLATELET TREATMENTS AFFECT THE POSITIVE PREDICTIVE VALUE OF IFOBT IN PATIENTS UNDERGOING COLORECTAL CANCER SCREENING? A NESTED CASE-CONTROL STUDY

2010 ◽  
Vol 42 ◽  
pp. S85
Author(s):  
G. Mandelli ◽  
F. Radaelli ◽  
S. Paggi ◽  
G. Gola ◽  
M. Gramegna ◽  
...  
2009 ◽  
Vol 15 (20) ◽  
pp. 2531 ◽  
Author(s):  
Shan-Rong Cai ◽  
Su-Zhan Zhang ◽  
Hong-Hong Zhu ◽  
Shu Zheng

2018 ◽  
Vol 154 (6) ◽  
pp. S-576
Author(s):  
Katherine Ni ◽  
Kelli O'Connell ◽  
Stephanie C. Yakoubovitch ◽  
Sanya Anand ◽  
Mengmeng Du ◽  
...  

2005 ◽  
Vol 5 (1) ◽  
Author(s):  
Paolo Giorgi Rossi ◽  
Antonio Federici ◽  
Francesco Bartolozzi ◽  
Sara Farchi ◽  
Piero Borgia ◽  
...  

In Vivo ◽  
2019 ◽  
Vol 33 (2) ◽  
pp. 573-579 ◽  
Author(s):  
CHIA-LING LIN ◽  
TA-CHUN LIU ◽  
YA-NI WANG ◽  
CHI-HSIANG CHUNG ◽  
WU-CHIEN CHIEN

Author(s):  
Huseyin Bilgin ◽  
Murat Haliloglu ◽  
Ali Yaman ◽  
Pinar Ay ◽  
Beliz Bilgili ◽  
...  

Purpose. The main purpose of this study was to investigate the dynamics of pentraxin 3 (PTX3) compared with procalcitonin (PCT) and C-reactive protein (CRP) in patients with suspicion of ventilator-associated pneumonia (VAP). Materials and Methods. We designed a nested case-control study. This study was performed in the Surgical Intensive Care Unit of a tertiary care academic university and teaching hospital. Ninety-one adults who were mechanically ventilated for >48 hours were enrolled in the study. VAP diagnosis was established among 28 patients following the 2005 ATS/IDSA guidelines. Results. The median PTX3 plasma level was 2.66 ng/mL in VAP adults compared to 0.25 ng/mL in non-VAP adults (p<0.05). Procalcitonin and CRP levels did not significantly differ. Pentraxin 3, with a 2.56 ng/mL breakpoint, had 85% sensitivity, 86% specificity, 75% positive predictive value, and 92.9% negative predictive value for VAP diagnosis (AUC = 0.78). Conclusions. With the suspicion of VAP, a pentraxin 3 plasma breakpoint of 2.56 ng/mL could contribute to the decision of whether to start antibiotics.


BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Luis A. García Rodríguez ◽  
Montse Soriano-Gabarró ◽  
Susan Bromley ◽  
Angel Lanas ◽  
Lucía Cea Soriano

Sign in / Sign up

Export Citation Format

Share Document